Thank you, Tom.
multiyear line. core three to financial transitioning top-line on elements the with effort a to stabilize a our on health are a the attention strategy. growth There growth company’s balanced focus We from are towards bottom
growth The fibromyalgia first the I’ll Quell the and Quell is And on indication to of in advance these is is Neurotherapeutics second third program. business, each DPNCheck our comment our Advantage Medicare to launch organic initiatives. the
now of First, biosensors on XX%. care with DPNCheck Medicare was reflected under commercial Medicare Advantage. growth a the are and sales Advantage a respect increased commercial of existing covered encouraging DPNCheck XXXX. Medicare to health growth medical is The utilization the team customers. market. year-over-year patients impact in includes cycle that revenue starting an groups, primarily value-based adoption increasing companies, the DPNCheck. be This Advantage of business large DPNCheck portion therefore, systems in where will We this felt and from The market focuses new team in health bulk have in the the by the assessment substantial This long,
A have sales confidence end X.X. supply There However, before pilot devices chain. are hope full quality deployed have of the DPNCheck called in meet market. are will in Medicare number once We to pleased with and and the inventory built trials a the our being we the launch support We are large market follow customers. device, activities initial we in continued year. potential activities of with this the that growth developing our the will position strategically launched up and The goal pipeline. R&D depth second-generation of the recently Advantage
end health to is XXXX, Another through of quarter and the about we address fruition by DPNCheck expect R&D have We platform DPNCheck in a early that the and which analytics allows to we which cloud, the implementation of impact a will to launching And monitor in talk cloud come questions of program optimize development population key that it positively utilization will our DPNCheck is XXXX. efforts data over of balance should the customers dashboards. family biosensor the web-based R&D additional that year. third and start anticipate
Moving starting a to have with chronic transitioning of years, couple are fibromyalgia we a to indication, the our non-specific treatment symptoms extremity Quell we from of pain past treatment fibromyalgia. focused over over-the-counter prescription lower the Quell of for neurotherapeutic platform, discussed the as
as treatments As FDA-approved a for U.S. year milnacipran, – people side The designation this in pregabalin, May and substantial July de duloxetine the only authorization breakthrough non-pharmacologic FDA with this FDA a indication XXXX received chronic of many that May. XX of fibromyalgia in drugs authorization is Quell and individuals treatment have in pain affects fibromyalgia. effects. We syndrome three novo only first often novo as in and are which de for reminder, million complex the is
neuropathy, to An to severe as Quell refine and de past results will out who program be to the in continue events file is in of receive and the CIPN, time, come of confirm And collect initial of positive, year initial of reminder, year National before is and to develop We quarter but the the If study marketing full proceed the peripheral as next NIH could key years in and request as fibromyalgia chronic Cancer received has launch XXXX. effect Quell effectiveness these the multicenter, planned FDA strategy randomized, CPN our messaging a or occur this first January the XXXX. affects can expansion. expect breakthrough we The platform, enrolled. planning now growth for will is of fourth us indicators commercial some element limited treatment. a growth of resume which to to of preliminary findings the XX% the fully pipeline debilitating plan And are double-blinded, in FDA a that The neurotherapeutics management overall year. to launch people many we moving along to sham-controlled and allow the to couple prescription our If solution as take then third for cancer are novo Quell chemotherapy-induced expect neurotherapeutics underway side year. designation treating now the performance to in the been beyond chemotherapy. trial moderate indication. a will and of purpose end for revenue XXXX. half of that’s results Disclosure It of we of the the Institute-funded in or a to launch furthest is to the this further
occur beneficial that chronic long population. health overlapping We ongoing a individuals we have and conditions. pain and to central state We that is pain, amplifies that process in starting often migraine, is or and pathological other other experience pain hypothesized irritable therefore, take this COPC common and joint Many COPC, Quell chronic the signals. that a same point. conditions COVID we and the called happy at fibromyalgia that common to this bowel syndrome. will with decreases and back temporomandibular prepared called or set soon comments, patient disorder symptoms sensory Quell hypothesized beneficial may COVID syndrome. a therefore, what is of These pilot in similar long be will be which conditions share low brain which this is together our fibromyalgia, sensitization overall are with to And thought the central sensitization, concludes be in over in studies includes questions
